Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Gold Fields Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $21.23 (market cap $3.67B), while Gold Fields Limited trades at $39.17 (market cap $33.80B). The key difference: Gold Fields Limited is far larger — about 9.2× ACADIA Pharmaceuticals Inc.'s market cap, and Gold Fields Limited pays a 5.5% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ACADIA Pharmaceuticals Inc. for 77 Days and Gold Fields Limited for 51 Days on average.
| ACAD | GFI | |
|---|---|---|
Market Cap | $3.67B | $33.80B |
Volume | 1,770,821 | 4,961,317 |
Sector | Health | Basic Materials |
52-Week High | $30.57 | $61.52 |
52-Week Low | $18.62 | $31.25 |
Typical Hold Time | 77 Days | 51 Days |
Enterprise Value | $2.76B | $34.40B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $21.24, down 1.07% over 24 hours, with a bullish technical signal and strong support at $21. The company reported robust revenue growth to $1.07B in 2025 and a net income margin of 30.13%, though a recent Phase II Alzheimer's study missed its primary goal, causing volatility. Positive developments include European approval for Daybue and a patent extension to 2041.
The outlook is mixed; strong profitability and analyst consensus favor upside to a $30.05 price target, but clinical trial setbacks and legal investigations pose significant risks. Investors should weigh solid fundamentals against pipeline uncertainty and sentiment shifts from recent news.
Gold Fields (GFI) trades at $37.83, up 2.94% today, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 38.66% net income margin and trades at a discounted P/E of 7.98. Recent news highlights the company's pursuit of a major acquisition with Northern Star, alongside record cash flow and shareholder returns. Analyst consensus is a Buy with a $46.33 price target, implying significant upside.
The outlook for GFI is positive, driven by strong operational performance, high gold prices, and disciplined capital returns. Key risks include execution of the Northern Star deal and gold price volatility. With solid earnings growth and a compelling valuation, the stock presents a favorable opportunity for investors seeking exposure to a high-margin gold producer.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
